share_log

东瑞制药(02348):伊努西单抗III期临床试验提前完成患者入组

Donui Pharmaceutical (02348): patients were enrolled in the III phase clinical trial of Inucil monoclonal antibody completed ahead of time.

鳳凰網港股 ·  Dec 22, 2021 06:00

Phoenix New Media Hong Kong Stock Market | Donui Pharmaceutical (02348) announced that the company has been informed by Congrong Oriental that a key registered phase III clinical trial of PCSK9 McAb (AK102) in the treatment of primary hypercholesterolemia and mixed hyperlipidemia in China has been completed ahead of schedule.

This clinical trial is one of three large-scale key registered clinical trials of inuximab in the treatment of primary hypercholesterolemia and mixed hyperlipidemia. The clinical trial is designed to cover the unmet clinical needs of a wide range of people, and is designed to evaluate the lipid-lowering efficacy and safety of inuximab in patients with cardiovascular very high-risk, high-risk and medium-low risk hyperlipidemia for a long time. To provide more basis for supporting the launch of products.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment